Illumina Inc.

Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. The company's products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The company's portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis.Co.'s portfolio of sequencing platforms represents a family of systems that are used by customers to perform whole-genome, de novo, exome and ribonucleic acid sequencing, and targeted resequencing of specific gene regions and genes.
  • TickerILMN
  • ISINUS4523271090
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

Colin Scarola

Illumina, Inc.

Illumina Inc: 1 director sold

A director at Illumina Inc sold 1,200 shares at 326.010USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

ValuEngine Rating and Forecast Report for ILMN

ValuEngine Rating and Forecast Report for ILMN

Colin Scarola

Illumina, Inc.

ValuEngine Rating and Forecast Report for ILMN

ValuEngine Rating and Forecast Report for ILMN

Colin Scarola

Illumina, Inc.

Colin Scarola

Illumina, Inc.

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior

Colin Scarola

Illumina, Inc.

Colin Scarola

Illumina, Inc.